Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Pharmaceuticals

Delayed Hong Kong S.E. 06:55:25 24/07/2024 BST 5-day change 1st Jan Change
2.790 HKD -0.71% Intraday chart for Luye Pharma Group Ltd. -2.79% -25.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Luye Pharma Group to Divest 34.8% Stake in Shenzhen Unit MT
Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. for CNY 1.0 billion. CI
Chinese Regulator Approves Luye Pharma Group's New Drug for Marketing MT
Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China CI
Luye Pharma Group Ltd. Announces Manufacturing Facility of Paliperidone Palmitate Extended-Release Injectable Suspension Passed Pai by U.S. FDA with No FDA-483 CI
Luye Pharma Secures Chinese Medical Regulatory Approval for Parkinson’s Disease Treatment MT
Luye Pharma Group Ltd. Announces Its Jinyouping ® (Rotigotine Microspheres for Injection, Ly03003) Developed by the Group Has Been Approved CI
China Grants Marketing Approval to Luye Pharma's Anti-Schizophrenia Tablets MT
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China CI
Luye Pharma's Japanese Partner Towa Files New Drug Application for Dementia Patch MT
Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610 CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3% MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List MT
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong MT
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong CI
Luye Pharma Group Ltd. Announces Board Changes CI
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao MT
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease MT
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China CI
Chart Luye Pharma Group Ltd.
More charts
Logo Luye Pharma Group Ltd.
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
Employees
5,270
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
2.618CNY
Average target price
2.822CNY
Spread / Average Target
+7.78%
Consensus
  1. Stock Market
  2. Equities
  3. 2186 Stock
  4. News Luye Pharma Group Ltd.
  5. China Grants Marketing Approval to Luye Pharma's Anti-Schizophrenia Tablets